Pacira BioSciences (PCRX) Long-Term Deferred Tax (2020 - 2026)

Pacira BioSciences' Long-Term Deferred Tax history runs 7 years deep, the most recent figure standing at $122.1 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax fell 5.34% year-over-year to $122.1 million; the TTM figure through Mar 2026 stood at $122.1 million (down 5.34% YoY), while the FY2025 annual figure was $123.9 million, down 5.0% from the prior year.
• Long-Term Deferred Tax was $122.1 million for Q1 2026 at Pacira BioSciences, down from $123.9 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $169.3 million in Q1 2022 to a low of $120.2 million in Q3 2025.
• Historically, Long-Term Deferred Tax has averaged $143.3 million across 5 years, with a median of $141.1 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax jumped 69.52% in 2022, then retreated 15.82% in 2024.
• A 5-year view of Long-Term Deferred Tax shows it stood at $160.3 million in 2022, then dropped by 9.87% to $144.5 million in 2023, then decreased by 9.77% to $130.4 million in 2024, then declined by 5.0% to $123.9 million in 2025, then slipped by 1.4% to $122.1 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $122.1 million (Q1 2026), $123.9 million (Q4 2025), and $120.2 million (Q3 2025), per Business Quant data.